Abstract

Many biological and biotechnological processes are controlled by protein–protein and protein–solvent interactions. In order to understand, predict, and optimize such processes, it is important to understand how solvents affect protein structure during protein–solvent interactions. In this study, all-atom molecular dynamics are used to investigate the structural dynamics and energetic properties of a C-terminal domain of the Rift Valley Fever Virus L protein solvated in glycerol and aqueous glycerol solutions in different concentrations by molecular weight. The Generalized Amber Force Field is modified by including restrained electrostatic potential atomic charges for the glycerol molecules. The peptide is considered in detail by monitoring properties like the root-mean-squared deviation, root-mean-squared fluctuation, radius of gyration, hydrodynamic radius, end-to-end distance, solvent-accessible surface area, intra-potential energy, and solvent–peptide interaction energies for hundreds of nanoseconds. Secondary structure analysis is also performed to examine the extent of conformational drift for the individual helices and sheets. We predict that the peptide helices and sheets are maintained only when the modeling strategy considers the solvent with lower glycerol concentration. We also find that the solvent-peptide becomes more cohesive with decreasing glycerol concentrations. The density and radial distribution function of glycerol solvent calculated when modeled with the modified atomic charges show a very good agreement with experimental results and other simulations at .

Highlights

  • IntroductionThe Rift Valley Fever Virus (RVFV) was first discovered in 1931 in the Great Rift Valley of Kenya, East Africa [1]

  • Because of the high economical burden of Rift Valley Fever Virus (RVFV) outbreaks, the possibility of severe disease without effective antiviral treatment options and the epidemic potential, the World Health Organization (WHO) has urged that Research and Development (R&D) efforts focus on this pathogen to develop medical countermeasures [3]

  • We focus on a C-terminal domain of the RVFV L protein

Read more

Summary

Introduction

The Rift Valley Fever Virus (RVFV) was first discovered in 1931 in the Great Rift Valley of Kenya, East Africa [1]. It is anarbovirus in the Bunyavirales order, Phenuiviridae family and Phlebovirus genus. Even though it was discovered in East Africa, it has spread and caused periodic outbreaks in human and livestock populations throughout Africa, and as far as into the Arabian Peninsula. Because of the high economical burden of RVFV outbreaks, the possibility of severe disease without effective antiviral treatment options and the epidemic potential, the World Health Organization (WHO) has urged that Research and Development (R&D) efforts focus on this pathogen to develop medical countermeasures [3]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call